Oncology Venture granted IDE approval for LiPlaCis DRP study 19 augusti, 2019 Oncology Venture have received an IDE approval from the FDA to use DRP for patient selection in a phase III study with the company’s drug candidate LiPlaCis. This is a huge step forward in Oncology Venture’s pu... LÄS MER!
